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Abstract
Objective High prevalence of exaggerated pulmonary
artery pressure response to exercise (EPAPR) was reported
in patients with systemic sclerosis (SSc). However, path-
ophysiology of this phenomenon has not been well defined.
Therefore, we evaluated the frequency and potential aeti-
ology of EPAPR in SSc patients.
Methods We included 85 patients (79 female, 6 male,
mean age 54.3 ± 13.9 years) with SSc. Transthoracic
echocardiography followed by exercise Doppler echocar-
diography (EDE) were performed. A positive EDE was
defined when at least 20 mmHg increase of tricuspid
regurgitation peak gradient (TRPG) was recorded. Right
heart catheterization (RHC) with exercise was performed
in positive EDE patients and in subjects with resting TRPG
[31 mmHg.
Results Resting TRPG [31 mmHg and/or positive EDE
was found in 30 patients and they were referred to RHC.
Finally, RHC was performed in 20 patients (16 pts resting
TRPG [31 mmHg and 4 others normal resting TRPG and
positive EDE). In 12 (60 %) of them an EPAPR with
elevated pulmonary capillary wedge pressure (PCWP) was
observed. Interestingly, mean left atrium (LA) diameter
was greater in an EPAPR with elevated PCWP patients
than in subjects with normal exercise response
(39.36 ± 5.6 vs. 35.53 ± 3.48, p = 0.03). In EPAPR with
elevated PCWP group greater mean value of E/E0 of mitral
lateral annulus was observed (7.98 ± 3.35 vs. 6.27 ± 1.94,
p = 0.03). In the univariate logistic regression analysis
increased LA diameter was significant predictor of EPAPR
with elevated PCWP (OR 1.199, 95 % CI 1.029–1.396,
p = 0.019).
Conclusions Despite very well-known risk of PAH in
systemic sclerosis patients, the excessive increase of PAP
during exercise is more commonly caused by left ventricular
diastolic dysfunction than pulmonary arterial vasculopathy.
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PAP Pulmonary arterial pressure
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TAPSE Tricuspid annular peak systolic
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TRPG Tricuspid regurgitation peak gradient
Introduction
Pulmonary hypertension (PH) is a well-known complica-
tion of systemic sclerosis and together with interstitial lung
diseases is the leading cause of SSc-related deaths. The
prevalence of pulmonary arterial hypertension in SSc
patients is 7–12 % [1, 2]. Early and proper diagnosis of
pulmonary hypertension (PH) in systemic sclerosis (SSc)
patients is very important for their outcome, because
patients with already advanced, symptomatic PH usually
have poor prognosis [3–6]. In one randomized controlled
trial was shown that therapeutic intervention at an early
stage of PH may be beneficial [7]. Recent data suggest that
there is an unexpectedly high prevalence of inappropriate
pulmonary artery pressure (PAP) responses to exercise in
patients with SSc [8–12]. However, its clinical significance
is still under discussion. According to the latest European
Guidelines definition of PH does not include exercise-
induced PH mainly due to lack of sufficient data [3]. Some
authors suggested that SSc patients with normal resting
PAP and excessive exercise increase in PAP present an
early stage of pulmonary arteriolar vasculopathy [13].
However, in this group of patients progressive cardiac
fibrosis impairing left ventricular (LV) diastolic function
was also reported [14, 15]. Therefore, we assumed that
impaired LV diastolic function present in SSc patients is
responsible for exaggerated PAP responses to exercise and
can lead to post-capillary hypertension.
Materials and methods
A group of 89 consecutive patients (82 females and 7
males, mean age 54.8 ± 13.6 years) with diagnosed SSc
(mean disease duration 9.0 ± 12.4 years, range
1–45 years, median 6 years) were enrolled in this pro-
spective study. The diagnosis of SSc was based on the
American College of Rheumatology criteria [16]. Diffuse
disease was found in 54 (61 %) patients and limited disease
in the remaining 35 (39 %) patients. Clinical character-
ization of patients with SSc was performed according to the
European Scleroderma Trial and Research (EUSTAR)
recommendations [17].
We did not include patients with coronary artery disease
(angina pectoris, previous myocardial infarction, ECG and/
or echocardiographic signs of myocardial ischemia), severe
systemic hypertension, LV hypertrophy (intraventricular
septum or posterior wall [11 mm at echocardiographic
examination) and with significant valvular heart disease.
Restrictive LV filling at resting echocardiography with an
average E/E0 [13 (or septal E/E0 C15 or lateral E/E0 [12)
was also an exclusion criterion [18]. We excluded patients
with significant pulmonary dysfunction defined as forced
vital capacity (FVC) and total lung capacity values\60 %
predicted and/or the forced expiratory volume in one sec-
ond to vital capacity ratio (FEV1/VC) \70 % predicted.
We also did not include patients with significant fibrotic
changes in the lung by high-resolution computed tomog-
raphy (Kazerooni fibrosis score C16). An impaired renal
function with creatinine clearance calculated by Modifi-
cation of Diet in Renal Disease Study Group (MDRD)
formula below 60 ml/min was also an exclusion criterion.
As a control group we assessed 21 age and sex-matched
subjects (18 females, 3 males, mean age 49.3 ±
10.5 years) with similar profile of coexisting systemic
hypertension and its treatment as the study group. These
subjects had no data for pulmonary diseases and presented
no echocardiographic evidence of structural heart disease.
All patients and control subjects gave informed consent,
and the protocol of the study was approved by the local
Institutional Ethics Committee (No. KB66/2006).
Echocardiography
Echocardiographic examination was performed with Phi-
lips iE 33 (Andover, Md., USA) with 2.5–3.5 MHz trans-
ducers. Using continuous-wave Doppler echocardiography,
the tricuspid regurgitation peak gradient (TRPG) was cal-
culated according to the simplified Bernoulli’s equation.
According to European Society of Cardiology (ESC) cri-
teria PH was suspected when TRPG[31 mmHg (tricuspid
regurgitant velocity [2.8 m/s) [5]. In order to assess the
814 Clin Res Cardiol (2013) 102:813–820
123
right ventricular function using the one-dimensional
M-mode echocardiography, the tricuspid annular peak
systolic excursion (TAPSE) was measured. The LV ejec-
tion fraction (EF) was calculated according to the modified
Simpson rule using apical four- and two-chamber views
[19].
Assessment of left ventricular diastolic function
Mitral valve inflow (MVF) was recorded in the apical four-
chamber view with Doppler gate positioned in the LV on
the level of the mitral valve edges. The following param-
eters were evaluated: peak velocity of the early inflow
phase (E), peak velocity of the atrial inflow phase (A) and
E/A ratio.
Tissue Doppler imaging (DTI) was performed in the
apical views to acquire mitral annular velocities. Lateral
annulus early diastolic velocity (Mit E0 lateral) and septal
annulus early diastolic velocity (Mit E0 septal) were mea-
sured. Moreover, mitral E/E0 lateral and septal were cal-
culated. E/E0 [13 (or septal E/E0 C15 or lateral E/E0 [12)
was defined as abnormal [18].
The exercise echocardiography protocol
and the methodology for measuring right ventricular
systolic pressure at rest and following exercise
The patient then performed a standard exercise on a
treadmill according to the Bruce protocol until 85 % of the
maximum heart rate was achieved. The exercise was then
stopped and the patient resumed the left lateral position as
soon as possible. In the apical four-chamber view, using
continuous-wave Doppler, the peak velocity of the tricus-
pid regurgitant wave was recorded and the TRPG was
calculated. The TRPG was recorded within 1 min after
stopping the exercise. PH was suspected when TRPG at
rest exceeded 31 mmHg (Vmax[2.8 m/s) or increased by
at least 20 mmHg versus baseline following exercise [13].
Patients with suspicion of PH were referred to right heart
catheter (RHC).
Hemodynamics assessment of the right heart
Cardiac catheterization was performed within 6 weeks of
exercise echocardiography according to the previously
described protocol [20]. The Swan-Ganz catheter was
passed under fluoroscopic guidance to the pulmonary
artery. The following variables were recorded: PAP (sys-
tolic, diastolic and mean), mean pulmonary capillary
wedge pressure (PCWP) and mean right atrial pressure.
Cardiac output was determined by thermodilution
injecting cooled saline until a variability of \10 % was
achieved in three consecutive measurements. The vascular
resistance values in the pulmonary and systemic circulation
were calculated using typical formulas. The exercise test
was performed on a cyclo ergometer in the lying position,
aiming to achieve the maximum load of 125 W. After
5 min of maximal tolerated exercise the same measure-
ments as those at rest were performed. A special attention
has been paid to the reliable measurement of PCWP. Tip of
the catheter was placed in distal part of the pulmonary
arterial tree and balloon was carefully filled with increasing
volume of air to avoid over wedge phenomenon. The
measurement was accepted, when rapid drop in PAP has
been obtained and biphasic pressure curve with respiratory
variation typical for wedge pressure was recorded. Digi-
tized mean values of PCPW were used for calculations at
rest and at exercise. We found it impossible to measure
PCPW at exercise using breath-hold technique or extract
end-expiratory values, because of high respiratory rate and
important fluctuations in intrathoracic pressure.
In accordance with the ESC recommendations, PAH at
rest was diagnosed when mPAP was C25 mmHg and
PCWP did not exceed 15 mmHg [5]. Exaggerated pul-
monary artery pressure response to exercise (EPAPR) with
normal PCWP was identified when mPAP during exercise
exceeded 30 mmHg in the presence of normal PCWP. The
venous PH at rest was diagnosed when mPAP at rest was
C25 mmHg and PCWP exceeded 15 mmHg [5]. Exag-
gerated pulmonary artery pressure response to exercise
(EPAPR) with elevated PCWP was diagnosed when mPAP
during exercise exceeded 30 mmHg and PCWP exceeded
20 mmHg [21].
Blood sampling and assays
Fasting blood samples were collected by venipuncture,
centrifuged and sera were stored at -70 C until assayed.
The concentration of NT-proBNP was analyzed on Elecsys
2010 automatic analyzer (Roche Diagnostics, Basel,
Switzerland). Serum NT-proBNP concentration higher than
125 pg/ml was regarded as abnormal as indicated by the
producer.
Statistical analysis
Data characterized by a normal distribution are expressed as
a mean followed by a standard deviation. Biochemical
parameters are expressed both as a mean followed by a
standard deviation and as a median with a range. Patients
with SSc and controls were compared with Wilcoxon test
depending on the character of parameters distribution. For
categorical variables, the differences between the groups
were compared with v2 test or Fisher’s exact test. Correla-
tions between echocardiographic and biochemical variables
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were evaluated by Spearman’s correlation coefficients.
Logistic regression analysis was done to assess the odds ratio
for abnormal exercise increase in post-capillary PAP.
An analysis was performed using a statistical software
package (SAS 9.2). p \ 0.05 was considered statistically
significant.
Results
None of the patients enrolled in our study had any clinical
symptoms at rest suggestive for PH. Fifteen (17 %) subjects
complained mild or moderate exertional dyspnoea. Due to
orthopaedic conditions preventing from undergoing an ade-
quate physical exercise 4 (4.5 %) patients were excluded.
Finally, a total of 85 SSc patients performed exercise test.
The general characteristics of 85 SSc patients and con-
trol group undergoing exercise echocardiography are
summarized in Table 1.
Treatment
Angiotensin-converting enzyme inhibitors (ACE-I)
received 23 (27 %) SSc patients, angiotensin II receptor
antagonists-5 (6 %), beta blockers-7 (8 %), diuretics-12
(14 %), calcium channel blockers-20 (23 %). Due to the
progression of SSc 12 (14 %) patients received immuno-
suppressant agents (glucocorticoids and cyclophospha-
mide). We did not find significant differences in the use of
the cardiovascular drugs between SSc and control group.
The main clinical, pulmonary function and serological
findings of SSc patients are shown in Table 2.
Echocardiographic data
In Table 3 the echocardiographic parameters in SSc group
and controls are presented.
The SSc patients presented lower mean value of mitral
E/A. We did not find significant differences between the
mean value of LA diameter and E/E0.
The main parameters recorded before and after exercise
test in SSc patients and controls are shown in Table 4.
The mean resting and exercise TRPG values and D
TRPG were significantly higher in SSc patients than in
controls.
Significant correlations between exercise TRPG and
echocardiographic indices are listed in Table 5.
Exercise echocardiography
Thirty (35 %) patients with TRPG exceeding 31 mmHg
at rest and/or an exercise increase in TRPG [20 mmHg
were referred for RHC. Eight refused to undergo the
procedure, one patient could not performed the proce-
dure due to a worsening of general condition and one







Age (years) 54.3 ± 13.9 49.3 ± 10.5 0.09
Gender (F/M), no. 79/6 18/3 0.38
Body surface area (m2) 1.73 ± 0.26 1.72 ± 0.18 0.7
Heart rate (bpm) 73.47 ± 9.45 76.21 ± 12.38 0.3
Blood pressure systolic
(mmHg)
125.7 ± 18.8 123.3 ± 15.4 0.57
Blood pressure diastolic
(mmHg)
76.4 ± 11 82.3 ± 12 0.02
Systemic hypertension
(%)
25 (29 %) 6 (29 %) 0.2
Table 2 Clinical, pulmonary function and serological data of 85 SSc
patients
Characteristics Mean Median, range
Disease duration (years) 9.0 ± 12.4 5.0 (1–25)
Rodnan score 6.4 ± 6.7 4.0 (1–35)
FVC, % predict 100.4 ± 18.3
FEV1, % predict 94.7 ± 19.7
FEV1/FVC, % predict 79.8 ± 8.2
TLC, % predict 101.9 ± 17.5
DLCO, % predict (n = 59) 70.7 ± 19.1
Autoantibodies No %
ANA positive 79 93
ACA positive 28 33
Anti- Topo I 40 48
FVC forced vital capacity, FEV1 forced expiratory volume in 1 s,
TLC total lung capacity, DLCO carbon monoxide diffusing capacity






EF (%) 65 ± 5.1 67 ± 2.52 0.01
LA 32.3 ± 4.52 31.1 ± 3.46 0.53
RV/LV 4 chambers 0.73 ± 0.12 0.66 ± 0.08 0.01
TAPSE (mm) 22.2 ± 3.23 24.14 ± 2.37 0.01
MAPSE (mm) 15.4 ± 2.4 16.3 ± 1.8 0.05
Mitral E/A 0.96 ± 0.3 1.2 ± 0.3 0.002
Mit E/E0 lateral mitral
annulus
7.55 ± 2.85 6.87 ± 2.3 0.4
EF ejection fraction, LA left atrium, RV right ventricle, LV left ven-
tricle, TAPSE tricuspid annulus plane systolic excursion, MAPSE
mitral annulus plane systolic excursion
816 Clin Res Cardiol (2013) 102:813–820
123
patient died due to bleeding from oesophageal varices
while awaiting the procedure. Finally, RHC was per-
formed in 20 patients (16 pts resting TRPG [31 mmHg
and four with normal resting TRPG and EPAPR). In 12
(60 %) of them an EPAPR with elevated PCWP was
observed (mean exercise mPAP 41.8 ± 13.2 mmHg,
mean exercise PCWP 25.1 ± 4.8 mmHg). In remaining
two PAH, one pulmonary venous hypertension and five
pts an EPAPR with normal PCWP was diagnosed
(Fig. 1). In all four patients with normal resting TRPG
and EPAPR, elevated PCWP during exercise was
observed.
Parameters obtained during RHC in SSc patients are
listed in Table 6.
In Table 7 clinical, echocardiographic and biochemical
parameters in SSc patients with EPAPR with elevated
PCWP and in the group of normal resting end exercise
TRPG are listed.
The mean LA diameter was significantly increased in
SSc patients with EPAPR with elevated PCWP than in
subjects with normal PAP values. Also the mean value of
E/E0 was higher in the former.
In the univariate logistic regression analysis we identi-
fied parameters that predicted EPAPR with elevated PCWP
(Table 8).
Discussion
Some data underline that an excessive increase in PAP
during exercise cannot be regarded as the norm [22, 23]. It
was even postulated that this is an early preclinical stage of
PH. Moreover, there are also reports showing beneficial
effects of bosentan treatment in asymptomatic patients, but
with excessive increase in PAP during exercise [24]. Steen
Table 4 The main parameters before and after exercise test in SSc
and controls
Parameter SSc (n = 85) Controls
(n = 21)
P value
HR (1/min) 84.4 ± 17.3 85.3 ± 17.2 0.68
Max exercise HR (1/min) 152.8 ± 22.9 165.3 ± 11.7 0.01
Workload (METS) 8.5 ± 2.66 10.91 ± 2.89 0.0008
HR max (%) 93.3 ± 13.8 96.6 ± 5.3 0.5
Resting TRPG (mmHg) 26.9 ± 6.3 17.8 ± 4.1 \0.0001
Exercise TRPG (mmHg) 39.0 ± 11.1 22.4 ± 8.4 \0.0001
D TRPG (mmHg) 12.5 ± 8.1 7.6 ± 4.5 0.02
TRPG tricuspid regurgitant peak gradient





E0 Lateral mitral annulus (cm/sek) -0.31 0.01
Mit E/E0 Lateral mitral annulus 0.3 0.01
Moreover the mean value of D TRPG correlates with LA diameter
(r = 0.33, p = 0.008)
Fig. 1 Qualification of patients
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and colleagues [13] evaluated 54 patients with SSc who
underwent exercise echocardiography. They showed
increase in exercise systolic PAP greater than 20 mmHg in
44 % of them. Also, Alkotob et al. [25] found an increase
in exercise systolic PAP in 46 % of the 65 patients with
SSc. Moreover, in a paper published by Pignone et al. [26]
authors showed exertional increase in systolic PAP above
40 mmHg in 18 (67 %) of 27 patients with SSc. In a
recently published paper Gargani et al. [12] exercise
Doppler echocardiography revealed significant exercise-
induced increase in PAP in 69 (42 %) among 164 SSc
patients with normal resting PAP. Exercise Doppler
echocardiography is useful not only in patients with SSc
but also in another population. Ha et al. [27] examined
during exercise echocardiography 396 patients with normal
left ventricular systolic function. They revealed that 135
(35 %) of them had systolic PAP [50 mmHg and it was
associated with E/E0 ratio.
Using standard rest and exercise echocardiography we
identified 30 patients with possible PH. Finally, RHC was
performed in 20 patients. Of these, four (20 %) patients
were qualified to the hemodynamic study because of the
excessive increase in PAP during exercise, with normal
resting values of TRPG. During the RHC 12 (60 %) patients
showed an EPAPR with elevated PCWP, while only in two
PAH was eventually diagnosed. Based on these observa-
tions, it seems that Doppler echocardiography is a useful
method to identify abnormal exercise-increased PAP in
patients with SSc. However, to determine the type of PH
requires cardiac catheterization. Only limited evidence
indicates that LV diastolic dysfunction may be the key
mechanism responsible for the inappropriate exercise-
increased PAP. Kovacs and colleagues [9] performed
echocardiographic exercise test in 52 patients with connec-
tive tissue disease (26 patients with SSc). In 26 patients,
despite normal values of systolic PAP at rest, exercise sys-
tolic PAP was increased up to [40 mmHg. Twenty-one
patients underwent RHC, which confirmed the normal sys-
tolic PAP at rest and exercise systolic PAP increased to
[40 mmHg in 19 of them. Of these eight cases during RHC
had elevated PCWP[20 mmHg. Saggar et al. [28] reported
a group of 57 SSc patients who had normal resting hemo-
dynamics and underwent subsequent exercise RHC. An
inappropriate exercise-induced venous increase in PAP was
reported in 12 (21 %) of them. D’Alto et al. [8] evaluated
172 patients with SSc without PH and without significant
LV diastolic dysfunction (E/E’\15). In the SSc group
authors found significantly higher mean value of resting
systolic PAP and systolic PAP recorded after exercise.
Interestingly, in patients with impaired diastolic function
(the lowest quartile of the values of E0/A’) the average value
of systolic PAP recorded after exercise was significantly
higher than in subjects with preserved diastolic function (the
highest quartile of the values of E0/A’) (p = 0.015). In
recently published paper, Hager et al. [29] performed RHC
in 173 SSc patients when resting echocardiographic PAP
were \40 but [40 mmHg after exercise. LV diastolic dys-
function was diagnosed in 47 patients. Our findings are
consistent with observations by D’Alto and Hager et al.
Moreover, we observed significant correlations between
exercise TRPG and echocardiographic indices of LV dia-
stolic dysfunction in SSc patients. The mean value of
exercise TRPG significantly positively correlated with the
LA dimension, the E/E0 lateral mitral annulus ratio and
negatively with a mean E’ lateral mitral annulus velocity.
Table 6 RHC parameters in SSc patients
Parameter (n = 20) Mean ±SD Median Range
s PAP (mmHg) 33.2 6.6 32.5 23.0–48.0
m PAP (mmHg) 21.1 4.2 20.5 15.0–29.0
s PAP exercise (mmHg) 59.7 18.8 55.0 38.0–115.0
m PAP exercise (mmHg) 43.0 12.7 41.0 30.0–82.0
PVR (Wood U) 2.02 0.9 1.79 1.07–4.46
PCWP (mmHg) 11.2 3.4 10.5 7.0–20.0
PCWP exercise (mmHg) 22.6 6.1 23.0 17.0–32.0
sPAP systolic pulmonary artery pressure, mPAP mean pulmonary
artery pressure, PVR pulmonary vascular resistance, PCWP pul-
monary capillary wedge pressure
Table 7 Clinical, echocardiographic and biochemical parameters in







exercise (n = 55)
p value
Age 59.6 ± 7.9 51.6 ± 13.3 0.03
LA (mm) 39.36 ± 5.6 35.53 ± 3.48 0.03
TAPSE (mm) 19.86 ± 3.02 22.26 ± 2.75 0.01
MAPSE (mm) 14.6 ± 1.63 15.62 ± 1.98 0.05




130.8, 57–2195 80.8, 14.07–584.4
TRPG tricuspid regurgitant peak gradient
* Wilcoxon test
Table 8 Parameters that increase the chance of EPAPR with ele-
vated PCWP
Parameter OR 95 % CI P value
TAPSE, 1 mm decrease 1.386 1.074–1.788 0.012
LA diameter, 1 mm increase 1.199 1.029–1.396 0.019
Age, 1 year increase 1.06 1.002–1.121 0.04
TAPSE, LA diameter, and patients’ age are the parameters that
increase the chance of EPAPR with elevated PCWP
818 Clin Res Cardiol (2013) 102:813–820
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We have also demonstrated a positive correlation between
the change of TRPG and LA dimension. These correlations
indicate a potential link between rest and exercise TRPG
and an impaired LV relaxation. We tried to define param-
eters potentially useful for differentiating patients with
EPAPR with elevated PCWP. Thus, this group was char-
acterized by significantly higher mean LA dimension and
greater value of the E/E’ lateral mitral annulus ratio. These
observations may support the hypothesis that diastolic dys-
function is one of the major causes of EPAPR with elevated
PCWP. It seems that progressive diastolic dysfunction does
not impair PH at rest; however, it can contribute to an
abnormal EPAPR with elevated PCWP. Moreover, there are
evidences that serum NT-proBNP level may be useful for
detection of LV diastolic dysfunction [30]. In our SSc
patients with EPAPR with elevated PCWP we have found
significantly higher concentrations of serum NT-proBNP
level, suggesting neurohormonal activation. In univariate,
logistic regression analysis we identified factors that
increase the chance of EPAPR with elevated PCWP, such as
LA diameter (1.199, 95 % CI 1.029–1.396, p = 0.019),
confirming the importance of diastolic dysfunction. Our
study is one of the first to show that among SSc patients
exaggerated pulmonary artery pressure responses to exercise
is predominantly caused by impaired LV relaxation.
Study limitations
Eight SSc patients had not consented to RHC which may
have influenced the results. Moreover, RHC was performed
within 6 weeks after exercise echocardiography which
might have resulted in changes of hemodynamic status of
patients during awaiting the procedure. On the other hand,
the clinical condition of patients while awaiting the RHC
was stable and drug treatment was not modified.
The control group was 5 years younger than the SSc
group (54.3 ± 13.9 vs. 49.3 ± 10.5 years). Although the
difference was not significant p = 0.09.
Conclusions
Despite very well-known risk of PAH in systemic sclerosis
patients, the excessive increase of PAP during exercise is
more commonly caused by left ventricular diastolic dys-
function than pulmonary arterial vasculopathy.
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